HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Ankylosing Spondylitis

A chronic inflammatory condition affecting the axial joints, such as the SACROILIAC JOINT and other intervertebral or costovertebral joints. It occurs predominantly in young males and is characterized by pain and stiffness of joints (ANKYLOSIS) with inflammation at tendon insertions.
Also Known As:
Spondylitis, Ankylosing; Ankylosing Spondylarthritis; Ankylosing Spondyloarthritis; Bechterew's Disease; Spondylitis Ankylopoietica; Spondyloarthritis Ankylopoietica; Ankylosing Spondylarthritides; Ankylosing Spondyloarthritides; Bechterews Disease; Marie Struempell Disease; Spondylarthritides, Ankylosing; Spondylarthritis, Ankylosing; Spondylitis, Rheumatoid; Spondyloarthritides, Ankylosing; Spondyloarthritis, Ankylosing; Bechterew Disease; Marie-Struempell Disease; Rheumatoid Spondylitis; Spondylarthritis Ankylopoietica
Networked: 7131 relevant articles (527 outcomes, 1255 trials/studies)

Relationship Network

Disease Context: Research Results

Related Diseases

1. Rheumatoid Arthritis
2. Psoriatic Arthritis
3. Psoriasis (Pustulosis Palmaris et Plantaris)
4. Arthritis (Polyarthritis)
5. Pain (Aches)

Experts

1. Sieper, Joachim: 109 articles (11/2022 - 01/2002)
2. van der Heijde, Désirée: 93 articles (11/2022 - 03/2003)
3. Braun, Jürgen: 85 articles (12/2021 - 01/2002)
4. Sieper, J: 85 articles (01/2019 - 02/2000)
5. Braun, J: 84 articles (02/2020 - 02/2000)
6. Baraliakos, Xenofon: 76 articles (11/2022 - 01/2004)
7. Inman, Robert D: 66 articles (11/2022 - 03/2003)
8. Deodhar, Atul: 65 articles (12/2022 - 09/2008)
9. Maksymowych, Walter P: 61 articles (01/2022 - 03/2002)
10. Reveille, John D: 57 articles (12/2022 - 03/2003)

Drugs and Biologics

Drugs and Important Biological Agents (IBA) related to Ankylosing Spondylitis:
1. Tumor Necrosis Factor-alpha (Tumor Necrosis Factor)IBA
2. Etanercept (Enbrel)FDA Link
3. Infliximab (Remicade)FDA Link
4. Adalimumab (Humira)FDA Link
5. Tumor Necrosis Factor InhibitorsIBA
05/01/2010 - "Patients had active disease, defined as a Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) score >or=4. While there was no clear response at week 24 in the group in whom TNF blockers had failed (30% had achieved an ASAS20 response, 10% had achieved an ASAS40 response, none had achieved partial remission according to the ASAS criteria, and none had achieved 50% improvement on the BASDAI [a BASDAI50 response] beyond an expected placebo response), we observed a good improvement in the TNF blocker-naive group at week 24 (50% had achieved an ASAS20 response, 40% had achieved an ASAS40 response, 30% had achieved partial remission according to the ASAS criteria, and 50% had achieved a BASDAI50 response). "
05/31/2012 - "The ASAS criteria evolved from the idea that the earlier the recognition of patients with ankylosing spondylitis, the better the efficacy of tumor necrosis factor blockers. "
07/01/2010 - "It could be shown that TNF-blockers are at least as effective in patients with axial nonradiographic spondyloarthritis when compared with established ankylosing spondylitis and that TNF-blockers are even more effective when used earlier in the course of the disease and in younger age. "
11/01/2008 - "In light of the impressive efficacy of tumor necrosis factor blockers in the treatment of ankylosing spondylitis, particularly in patients with short disease duration, defining outcome parameters to monitor the structural damage of the disease has become more pertinent. "
12/04/2018 - "Factors associated with ASDAS remission in a long-term study of ankylosing spondylitis patients under tumor necrosis factor inhibitors."
6. C-Reactive ProteinIBA
01/01/2021 - "The clinical values of erythrocyte sedimentation rate (ESR), C-reactive protein (CRP), Bath Ankylosing Spondylitis Disease Activity Index (BASDAI), Harris hip score, and Ankylosing Spondylitis Disease Activity Score (ASDAS)-ESR in both groups showed significant clinical remission at week 52 (p < 0.001). "
01/01/2020 - "Improvement in HRQOL measured by SF-6D was associated with younger age, higher education, low Bath Ankylosing Spondylitis (BAS) Activity Index (BASDAI), high BAS Patient Global Score and high C-reactive protein; improvement in SF-36 PCS was associated with younger age, higher education, low BASDAI and no use of biological treatment at baseline. "
01/01/2017 - "Sustained improvements were observed in all other end points, including Bath Ankylosing Spondylitis Disease Activity Index, AS Disease Activity Score with C reactive protein inactive disease, ASAS 5/6, Short Form-36 Physical Component Summary and ASAS partial remission. "
10/01/2023 - "The primary endpoint, assessed at 6 months, included the proportion of patients attaining LDA and/or remission (Disease Activity Score for 28 joints based on C-reactive protein [DAS28-CRP] ≤ 3.2), minimal disease activity (MDA; MDA criteria), and moderate disease activity (Bath Ankylosing Spondylitis Disease Activity Index [BASDAI] score 4-7), respectively. "
09/20/2023 - "Rates for 12-month drug retention and 6-month remission (Ankylosing Spondylitis Disease Activity Score C-reactive protein inactive disease (ASDAS-ID)) were assessed in second and third TNFi-series and stratified by withdrawal reason. "
7. Non-Steroidal Anti-Inflammatory Agents (NSAIDs)IBA
8. secukinumabIBA
9. Sulfasalazine (Azulfidine)FDA LinkGeneric
10. golimumabFDA Link

Therapies and Procedures

1. Therapeutics
2. Osteotomy
3. Biological Therapy
07/01/2017 - "Recommendations 3 to 7 deal with the definition of active disease (including the recommended threshold of 2.1 for the Ankylosing Spondylitis Disease Activity Score [ASDAS] or the threshold of 4 [0-10 scale] for the Bath Ankylosing Spondylitis Disease Activity Index [BASDAI]), conventional treatment failure (nonsteroidal anti-inflammatory drugs being the first-line drug treatment), assessment of response to treatment (based on an ASDAS improvement  of at least 1.1 units or a BASDAI improvement of at least 2 units [0-10 scale] or at least 50%), and strategy in the presence of an inadequate response (where switching is recommended) or in the presence of long-term remission (where a process of biological therapy optimization can be considered, either a gradual increase in the interval between doses or a decrease of each dose of the biological therapy). "
03/01/2014 - "The likelihood of continued remission after the cessation of a biological therapy is much lower in ankylosing spondylitis."
01/01/2015 - "By this study, we aimed to compare Assessment in Ankylosing Spondylitis Response Criteria 20 response patterns (ASAS20) between subcutaneous approved biological agents in patients affected by ankylosing spondylitis by means of a mixed treatment comparison of different randomized controlled trials (RCTs) on the efficacy of biological therapies. "
01/01/2012 - "To compare ASAS (Assessment in Ankylosing Spondylitis Response Criteria), 20 response patterns between anti-TNF biological agents in patients with ankylosing spondylitis by means of a mixed treatment comparison of different randomized, controlled trials (RCTs) on the efficacy of biological therapies. "
12/01/2016 - "Biologic therapies have improved the clinical management of ankylosing spondylitis (AS). "
4. Moxibustion
5. Hip Replacement Arthroplasty (Total Hip Replacement)